0001628280-24-008951.txt : 20240305 0001628280-24-008951.hdr.sgml : 20240305 20240305164049 ACCESSION NUMBER: 0001628280-24-008951 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOYER ANDREW S CENTRAL INDEX KEY: 0001239546 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 24721410 MAIL ADDRESS: STREET 1: C/O WATSON PHARMA INC STREET 2: 360 MOUNT KEMBLE AVE CITY: MORRISTOWN STATE: NJ ZIP: 07960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 wk-form4_1709674816.xml FORM 4 X0508 4 2024-03-01 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001239546 BOYER ANDREW S C/O AMNEAL PHARMACEUTICALS, INC. BRIDGEWATER NJ 08807 0 1 0 0 Executive Vice President 0 Class A Common Stock 2024-03-01 4 M 0 31371 A 291217 D Class A Common Stock 2024-03-01 4 F 0 16219 5.47 D 274998 D Class A Common Stock 2024-03-03 4 M 0 39251 A 314249 D Class A Common Stock 2024-03-03 4 F 0 19665 5.47 D 294584 D Class A Common Stock 2024-03-03 4 M 0 49694 A 344278 D Class A Common Stock 2024-03-03 4 F 0 24897 5.47 D 319381 D Restricted Stock Units 2024-03-01 4 M 0 31371 0 D Class A Common Stock 31371 31371 D Restricted Stock Units 2024-03-03 4 M 0 39251 0 D Class A Common Stock 39251 78503 D Restricted Stock Units 2024-03-03 4 M 0 49694 0 D Class A Common Stock 49694 149083 D Restricted Stock Units 2024-03-04 4 A 0 152778 0 A Class A Common Stock 152778 152778 D Performance-Based Restricted Stock Units 2024-03-04 4 A 0 305556 0 A Class A Common Stock 305556 305556 D Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. On March 1, 2021, the reporting person was granted 125,483 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. On March 3, 2022, the reporting person was granted 157,005 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. On March 3, 2023, the reporting person was granted 198,777 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units vest in four equal annual installments beginning on March 4, 2025. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 152,778 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. /s/ Denis Butkovic, Attorney-in-Fact 2024-03-05